Ciprofloxacin labeling information includes a boxed warning regarding an increased risk of tendinitis and tendon rupture. What other form of information should be provided to the patient?

A drug development guide typically contains information regarding the research, clinical trials, and regulatory approvals of a drug. While informative, it is not designed for patient use and does not provide relevant safety or usage information for individuals taking ciprofloxacin.

Efficacy information focuses on how well a drug works for its intended purpose. While understanding efficacy is important, it does not address critical safety concerns such as the risks of tendinitis and tendon rupture that are vital for patient awareness when using ciprofloxacin.

Prescribing information is primarily intended for healthcare providers and includes detailed dosing, contraindications, and adverse effects. Although it contains important safety data, it is not directly provided to patients and may not be easily understood by them without professional guidance.